Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients. (21st October 2017)

• Record Type: Journal Article
• Authors: Hocker, James R.; Deb, Subrato J.; Li, Min; Lerner, Megan R.; Lightfoot, Stan A.; Quillet, Aurelien A.; Hanas, R. Jane; Reinersman, Matthew; Thompson, Jess L.; Vu, Nicole T.; Kupiec, Thomas C.; Brackett, Daniel J.; Peyton, Marvin D.; Dubinett, Stephen M.; Burkhart, Harold M.; Postier, Russell G.; Hanas, Jay S.
• Is Part Of: Cancer investigation. Volume 35:Number 9(2017)
• Page Start: 573
• Page End: 585
• Publication Date: 2017-10-21
• Subjects: ; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2017.1373120
• Languages: English
• ISSNs: 0735-7907

Abstract

ABSTRACT: A stage I non-small cell lung cancer (NSCLC) serum profiling platform is presented which is highly efficient and accurate. Test sensitivity (0.95) for stage I NSCLC is the highest reported so far. Test metrics are reported for discriminating stage I adenocarcinoma vs squamous cell carcinoma subtypes. Blinded analysis identified 23 out of 24 stage I NSCLC and control serum samples. Group-discriminating mass peaks were targeted for tandem mass spectrometry peptide/protein identification, and yielded a lung cancer phenotype. Bioinformatic analysis revealed a novel lymphocyte adhesion pathway involved with early-stage lung cancer.